

Page 9, line 18, delete "Sn" and insert therefor --56--.

Page 10, line 2, after "followed by rest of therapy on day,", delete "1" and insert --2--.

Page 14, lines 8 and 18, delete "Rituximab®" and insert therefor at each occurrence

--RITUXAN®--.

Page 15, last line, delete "Rituximab®" and insert therefor --RITUXAN®--.

Page 15, line 13, delete "http://www.cancernetwork.com" and insert therefor --See

O'Brien et al. (1996) Ann. Oncol. 7 Suppl. 6: S27-33; and Keating et al.

(1994) Drugs 47 Suppl. 6: 39-49, (1993) Semin. Oncol. 20 (5 Suppl. 7): 13-20,

and (1988) Nouv. Rev. Fr. Hematol. 30 (5-6): 461-65.

A 2
Page 16, lines 4, 5, 8 (both occurrences), 9, 12 and 13, delete "Rituximab®" and
insert therefor at each occurrence --RITUXAN®--.

IN THE CLAIMS:

Please amend Claims 1, 8, 11 and 12 as follows:

A 3
1. (Amended) A method of treating a hematologic malignancy associated with high numbers of circulating tumor cells by administering a therapeutically effective amount of an anti-CD20 antibody or antigen-binding fragment thereof, said amount being effective to achieve a reduction in circulating tumor cells.

A 4
8. (Amended) The method of Claim 3, wherein said antibody is administered in combination with at least one treatment selected from the group consisting of radiation, chemotherapy, [and/or] and lymphokine administration, and wherein said lymphokine administration serves to upregulate the expression of CD20 on tumor cells.